Lee:Publications: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
(→2013) |
(→2014) |
||
(23 intermediate revisions by the same user not shown) | |||
Line 3: | Line 3: | ||
|-valign="top" | |-valign="top" | ||
|style="background:#ffffff"| | |style="background:#ffffff"| | ||
==2014== | |||
# Nagathihalli NS, Beesetty Y, Lee W, Washington MK, Chen X, Lockhart AC, Merchant NB. Novel Mechanistic Insights into Ectodomain Shedding of EGFR Ligands Amphiregulin and TGF-α: Impact on Gastrointestinal Cancers Driven by Secondary Bile Acids. Cancer Res 74(7):2062-72 (2014) (PMID: 24520077, PMCID: PMC3975694) | |||
# Park JE, Wu Y, Carmony KC, Miller Z, Sharma LK, Lee D, Kim D, Lee W, Kim K. A FRET-based approach for identification of proteasome catalytic subunit composition. Mol BioSyst 10(2):196-200 (2014) (PMID: 24301521) | |||
# Wang-Gillam A, Thakkar N, Lockhart AC, Williams K, Baggstrom M, Naughton M, Suresh R, Ma C, Tan B, Lee W, Jiang X, Mwandoro T, Trull L, Belanger S, Creekmore AN, Gao F, Fracasso PM, Picus J. A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies. Cancer Chemother Pharmacol 74(2):419-26 (2014) (PMID: 24916546). | |||
# Miller Z, Lee W, Kim KB. The Immunoproteasome as a Therapeutic Target for Hematological Malignancies, Current Cancer Drug Targets, 14(6):537-48 (2014). (PMID: 25059201) | |||
# Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC. Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers, PLOS ONE, 18;9(9):e107424 (2014). (PMID: 25232828) | |||
# Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Caron WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris III HA, Zamboni WC. Factors Affecting the Pharmacokinetics (PK) and Pharmacodynamics (PD) of PEGylated Liposomal Irinotecan (IHL-305) in Patients with Advanced Solid Tumors, International Journal of Nanomedicine. Accepted (2014) | |||
# Carmony KC, Sharma LK, Lee DM, Park JE, Lee W, Kim, KB., Elucidating the catalytic subunit composition of distinct proteasome subtypes: A crosslinkling approach employing bifunctional activity-based probes, ChemBioChem, in press (2014) | |||
==2013== | ==2013== | ||
# Thakkar N, Kim K, Jang ER, Han S, Kim K, Kim D, Merchant N, Lockhart AC, Lee W. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm. 2013;10(1):406-416. (PMID:23215050) | # Thakkar N, Kim K, Jang ER, Han S, Kim K, Kim D, Merchant N, Lockhart AC, Lee W. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm. 2013;10(1):406-416. (PMID:23215050) | ||
# Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des 2013;19(2):4140-4151. (PMID: 23181576) | # Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des 2013;19(2):4140-4151. (PMID: 23181576) | ||
# Park JE, Ao L, Miller Z, Kim K, Wu Y, Jang ER, Lee EY, Kim KB, Lee W. PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit β1i expressed in multiple types of solid cancer. PLoS One ( | # Park JE, Ao L, Miller Z, Kim K, Wu Y, Jang ER, Lee EY, Kim KB, Lee W. PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit β1i expressed in multiple types of solid cancer. PLoS One 8(9):e73732 (2013) (PMID: 24040045) | ||
# Han S*, Kim K*, Thakkar N*, Kim D, Lee W. Role of Hypoxia Inducible Factor-1α in the Regulation of the Cancer-Specific Variant of Organic Anion Transporting Polypeptide 1B3 (OATP1B3) in Colon and Pancreatic Cancer. Biochem Pharmacol 2013;86:816-823 (*, equally contributed) (PMID: 23924606) | # Han S*, Kim K*, Thakkar N*, Kim D, Lee W. Role of Hypoxia Inducible Factor-1α in the Regulation of the Cancer-Specific Variant of Organic Anion Transporting Polypeptide 1B3 (OATP1B3) in Colon and Pancreatic Cancer. Biochem Pharmacol 2013;86:816-823 (*, equally contributed) (PMID: 23924606) | ||
# Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris III HA, Zamboni WC. Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. J Clin Pharmacol ( | # Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris III HA, Zamboni WC. Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. J Clin Pharmacol 69(12):2073-81(2013) (PMID: 23989300). | ||
==2012== | ==2012== | ||
# Jang ER, Lee N, Han S, Wu Y, Kumar Sharma L, Carmony KC, Marks J, Lee D, Ban J, Wehenkel M, Hong JT, Kim KB, Lee W. Revisiting the role of the immunoproteasome in the activation of the canonical NF-κB pathway. Mol Biosyst. 2012 Sep 31;8(9):2295-2302. (PMID:22722901) | # Jang ER, Lee N, Han S, Wu Y, Kumar Sharma L, Carmony KC, Marks J, Lee D, Ban J, Wehenkel M, Hong JT, Kim KB, Lee W. Revisiting the role of the immunoproteasome in the activation of the canonical NF-κB pathway. Mol Biosyst. 2012 Sep 31;8(9):2295-2302. (PMID:22722901) | ||
# Kumar Sharma L, Lee N, Jang ER, Lei B, Zhan C-G, Lee W, Kim KB. | # Kumar Sharma L, Lee N, Jang ER, Lei B, Zhan C-G, Lee W, Kim KB. Activity-based near-infrared fluorescent probe for LMP7: a chemical proteomics tool for the immunoproteasome in living cells. Chembiochem. 2012;13(13):1899-903. (PMID:22807337) | ||
# Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee D, Kim KB, Lee W. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol. Pharmaceutics 2012;9:2197−2205 (PMID: 22734651) | # Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee D, Kim KB, Lee W. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol. Pharmaceutics 2012;9:2197−2205 (PMID: 22734651) | ||
# Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol 2012 Nov;70(5):699-705 (PMID: 22941375). | # Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol 2012 Nov;70(5):699-705 (PMID: 22941375). |
Revision as of 18:30, 2 November 2014
2014
2013
2012
2011
2010
2009
2008
<2007
|